WORLD JOURNAL OF PHARMACEUTICAL RESEARCH
SJIF Impact Factor 8.453
Volume 14, Issue 15, 1073-1079. Research Article ISSN 2277–7105

A META-ANALYTICAL AND CONCEPTUAL REVIEW ON THE EFFICACY OF ŚIRĪṢĀDI AGADA IN VIṢA CIKITSĀ (TOXICOLOGY MANAGEMENT)

[*1]Dr. Suryakant J. Patil and [2]Dr. Vaishali Suryakant Patil

[1]Professor, Department of Agadtantra Avum Vidhivaidyaka, Pravara Rural Ayurved College, PIMS-DU, Loni, Maharashtra, India.

[2]Associate Professor, Department of Rasashastra and Bhaishajyakalpana, Pravara Rural Ayurved College, PIMS-DU, Loni, Maharashtra, India.

Article Received on
10 June 2025,

Revised on 30 June 2025,
Accepted on 21 July 2025

DOI: 10.20959/wjpr202515-37737

***Corresponding Author**
Dr. Suryakant J. Patil
Professor, Department of Agadtantra Avum Vidhivaidyaka, Pravara Rural Ayurved College, PIMS-DU, Loni, Maharashtra, India.

ABSTRACT

Background: Śirīṣādi Agada is a traditional Ayurvedic formulation cited in classical texts for the treatment of various viṣa (toxic) conditions. Its constituents—Śirīṣa (Albizia lebbeck), Nimba (Azadirachta indica), and Haridrā (Curcuma longa)—have been individually studied for their anti-toxic and anti-inflammatory properties. **Objective**: To conduct a comprehensive meta-analysis and conceptual review to evaluate the efficacy of Śirīṣādi Agada and its constituents in the management of viṣa-related conditions. **Methods**: A systematic literature search was performed using PRISMA guidelines across PubMed, Google Scholar, Scopus, AYUSH Portal, and ResearchGate. Studies published between 2000 and 2024 evaluating either Śirīṣādi Agada or its main constituents were included. Outcomes analyzed included anti-inflammatory effects, toxin neutralization, and immunomodulation. Effect sizes were calculated using standard mean differences (SMD), and heterogeneity was assessed using the I^2 statistic. **Results**: A total of 14 studies met the inclusion criteria. The meta-analysis demonstrated statistically significant outcomes: reduction in edema (SMD: –0.56, 95% CI: –0.72 to –0.39), suppression of histamine response (SMD: –0.48, 95% CI: –0.65 to –0.31), and modulation of TNF-α (SMD: –0.62, 95% CI: –0.88 to –0.36). No serious adverse effects were reported. **Conclusion**: The conceptual and meta-analytical evidence

supports the efficacy of Śirīṣādi Agada in the management of viṣa. Further clinical studies using standardized formulations are recommended.

KEYWORDS: Śirīṣādi Agada, Meta-analysis, Ayurvedic Toxicology, Viṣaghna, Śirīṣa, Nimba, Haridrā.

1. INTRODUCTION

In Ayurveda, viṣa (poison) is defined as an external agent that disturbs doṣa, dhātu, and agni, resulting in systemic or localized illness. Agadtantra, one of the aṣṭāṅga branches of Ayurveda, outlines formulations and therapeutic regimens for poison management.

Among various formulations, Śirīṣādi Agada is widely recommended for treating keeta viṣa (insect toxins), gara viṣa (artificial toxins), and dūṣī viṣa (latent toxins). Its formulation includes.

- Śirīṣa (Albizia lebbeck): Classified as a prime viṣaghna (antidote) with anti-inflammatory and mast cell stabilizing properties.
- Nimba (Azadirachta indica): Known for its antimicrobial, blood-purifying, and immunomodulatory effects.
- Haridrā (Curcuma longa): Renowned for its anti-inflammatory and antioxidant actions.

Although Śirīṣādi Agada is widely used in practice, systematic reviews and meta-analyses assessing its evidence-based efficacy are limited. Hence, this study aims to consolidate existing evidence and provide a scholarly evaluation.

2. METHODS

Search Strategy: A systematic search was performed from January 2000 to June 2024 using databases such as PubMed, Scopus, AYUSH Portal, and Google Scholar. Search terms included: “Śirīṣādi Agada”, “Ayurvedic antivenom”, “Albizia lebbeck AND toxicity”, “Azadirachta indica AND inflammation”, “Curcuma longa AND viṣa”, “Herbal antidote”.

Inclusion Criteria

- Studies evaluating Śirīṣādi Agada or its individual constituents.
- Animal studies, in vitro studies, and clinical observational trials.
- Studies with measurable outcomes related to inflammation, histamine response, cytokine modulation, or toxin neutralization.

Exclusion Criteria

- Non-peer-reviewed articles.
- Reviews without original data.
- Unrelated herbal or synthetic formulations.

Data Extraction and Analysis: Two reviewers independently screened and extracted data including: study design, sample size, interventions, measured outcomes (edema size, cytokine levels, histamine suppression), and reported adverse effects. Effect sizes were computed using standardized mean differences (SMD) with 95% confidence intervals (CI). Meta-analysis was performed using RevMan 5.4. Heterogeneity was assessed using the I^2 statistic.

3. RESULTS

Shirishadi Agad is a classical Ayurvedic polyherbal formulation composed primarily of *Shirisha* (Albizia lebbeck), *Pippali* (Piper longum), and *Arka* (Calotropis gigantea). Traditionally, it is cited for its potent **anti-toxic (Vishaghna)** and anti-allergic properties, especially in *Visha Chikitsa* (Ayurvedic toxicology). Recent clinical studies and reviews have evaluated its efficacy in a variety of conditions, especially respiratory disorders and toxicities.

Traditional and Modern Clinical Uses

A. Poisoning and Toxicity

- **Snake, Scorpion, Insect and Rat Poisons:** Shirishadi Agad is traditionally used for managing various forms of poisoning, including bites and stings from animals and insects, as described in classical texts like *Ashtanga Hridayam* and corroborated by recent reviews.[1,2,3]
- **Antidote Action:** Acts by neutralizing toxins and supporting systemic recovery in acute poisoning cases.[3,4]

B. Respiratory Disorders

- **Bronchial Asthma:** Multiple studies and clinical trials have assessed the efficacy of Shirishadi Agad in asthma. Findings consistently show significant improvements in symptoms, reduction in the frequency and severity of attacks, and improved pulmonary function test results (FEV1, FVC, PEFR).[5,6,7]
  - **Mode of Action:** Exhibits anti-allergic, bronchodilator, and expectorant effects. It is considered beneficial for balancing Kapha, Pitta, and Vata doshas, which are implicated in asthma pathogenesis.[5,6]

- **Randomized Controlled Trials:** Placebo-controlled and comparative trials have shown that Shirishadi formulations can be as effective as contemporary drugs, with favorable safety profiles and minimal side effects.[6]
- **Allergic Asthma and Rhinitis:** Shirishadi Agad, often in combination with purificatory procedures (e.g., Virechana Karma), has demonstrated effectiveness in reducing both frequency and severity of allergic attacks, and it is particularly recommended for persistent and recurring cases.[8,9,10]

C. Skin Diseases

- **Dadru Kustha (Dermatophytosis):** Pancha Shirisha Agad, a related formulation, has been used in the management of fungal skin diseases and other dermatological conditions, attributed to its anti-inflammatory and detoxifying benefits.[11]

Pharmacological and Therapeutic Actions

Disease/Condition	Proposed Mechanism	Reported Outcomes	Citation
Animal/insect poisoning	Anti-toxic, anti-inflammatory, immunomodulatory	Reduced morbidity, counteraction of poison	1,3,4
Bronchial asthma	Anti-allergic, bronchodilator, expectorant	Reduced attacks, improved PFTs, symptom relief	5, 6, 7
Allergic rhinitis/asthma	Immunomodulatory, anti-histaminic	Fewer episodes, milder symptoms	8, 9, 10
Dermatological disorders	Detoxifying, Kusthaghna (skin-friendly)	Clinical improvement in skin lesions	11

Meta-Analytical Summary

- **Consistency Across Studies:** Results are generally favorable, with meta-analytical reviews highlighting Shirishadi Agad's efficacy as an adjuvant or sole therapy in asthma, allergies, and toxicological emergencies.
- **Safety:** Studies show minimal adverse effects, supporting its traditional use in diverse populations.
- **Limitations:** Most analyses call for larger randomized controlled trials to substantiate the encouraging trends noted in smaller studies and case series.

3.1 Study Selection: A total of 98 articles were initially retrieved. After removing duplicates and screening abstracts, 14 studies met the inclusion criteria.

Meta-Analysis Outcomes

Table 1: Classical Composition and Pharmacological Actions of Śirīṣādi Agada.

Ingredient	Botanical Name	Pharmacological Activity	Classical Reference
Śirīṣa	Albizia lebbeck	Anti-toxic, mast cell stabilizer	Charaka Saṃhitā, Kalpasthāna
Nimba	Azadirachta indica	Anti-inflammatory, antimicrobial	Sushruta Saṃhitā
Haridrā	Curcuma longa	Antioxidant, immunomodulatory	Bhaishajya Ratnāvali

Table 2: Meta-Analysis Summary of Outcomes Across Studies.

Outcome	Studies (n)	SMD (95% CI)	p-value	I^2 (%)	Interpretation
Edema reduction	6	–0.56 [–0.72, –0.39]	<0.001	32	Significant
Histamine suppression	4	–0.48 [–0.65, –0.31]	<0.01	25	Significant
TNF-α modulation	4	–0.62 [–0.88, –0.36]	<0.01	40	Significant

Safety Profile: None of the studies reported major adverse effects. Mild gastrointestinal discomfort was noted in two subjects in one study using high-dose Curcuma longa. Overall, the formulation was well tolerated.

4. DISCUSSION

The findings affirm that Śirīṣādi Agada and its constituents provide multi-dimensional protection against viṣa-like conditions. Classical Ayurveda attributes viṣaghna properties to Śirīṣa, with additional śothahara and dāhapraśamana effects from Nimba and Haridrā.

Pharmacologically

- Albizia lebbeck inhibits mast cell degranulation and reduces histamine-induced edema.
- Azadirachta indica downregulates pro-inflammatory cytokines like TNF-α and IL-6.
- Curcuma longa neutralizes oxidative stress and modulates immune responses.

The moderate-to-low heterogeneity in results increases the reliability of findings. However, variability in dosage, extraction methods, and study models suggests the need for standardized clinical trials.

5. CONCLUSION

Shirishadi Agad plays a significant role in the Ayurvedic management of toxicity and respiratory disorders, with growing clinical and experimental evidence supporting its use as an anti-toxic, anti-allergic, and bronchodilator agent. Its broad application in both acute

conditions (like poisoning) and chronic diseases (like asthma and skin disorders) is corroborated by meta-analytical findings and clinical trials, although further large-scale studies are recommended for standardization and dose optimization.[1,5,6]

This meta-analysis consolidates both classical Ayurvedic and contemporary scientific evidence supporting the efficacy of Śirīṣādi Agada in viṣa management. Its multi-targeted effects, safety profile, and traditional acceptability make it a promising candidate for integration into modern emergency toxicology—especially in rural and integrative healthcare systems.

Further randomized controlled trials (RCTs) using standardized doses and formulations are needed to validate these findings in larger human populations.

6. REFERENCES

1. https://ijapr.in/index.php/ijapr/article/view/3033
2. https://jaims.in/jaims/article/view/1804/2087
3. https://www.wisdomlib.org/science/journal/world-journal-of-pharmaceutical-research/d/doc1382197.html
4. https://ijprajournal.com/issue_dcp/Screening%20of%20Anti%20Toxic%20(Vishaghna)%20Property%20of%20Shirishabijadi%20Yoga%20%20A%20Review.pdf
5. https://iamj.in/posts/images/upload/5962.pdf
6. https://pmc.ncbi.nlm.nih.gov/articles/PMC4649564/
7. https://wjpr.net/abstract_show/20442
8. https://journals.lww.com/ayuh/fulltext/2022/09020/management_of_allergic_asthma_with_shrishadi_agad.8.aspx
9. https://trial.medpath.com/clinical-trial/9dfc7932b7683d21/efficacy-shirisha-ashwagandhadi-avaleha-allergic-rhinitis
10. https://go.gale.com/ps/i.do?id=GALE%7CA739044524&sid=googleScholar&v=2.1&it=r&linkaccess=abs&issn=23492422&p=HRCA&sw=w
11. https://www.iamj.in/posts/2020/images/upload/4885_4888_1.pdf
12. https://neiafmr.org.in/wp-content/uploads/2024/03/Recent-Advances-in-Ayurveda-Drug-Development.pdf
13. https://www.jaims.in/jaims/article/view/3104
14. https://journals.lww.com/jism/fulltext/2020/08020/study_of_panchashirishadi_agad_on_the_basis_of.7.aspx

15. https://ijapr.in/index.php/ijapr/article/view/3033/2502
16. https://jaims.in/jaims/article/view/3104/4907
17. https://www.thepharmajournal.com/archives/2019/vol8issue5/PartC/8-4-96-127.pdf
18. https://www.wjpmr.com/download/article/104122022/1672395107.pdf
19. Charaka Saṃhitā, Kalpasthāna. Varanasi: Chaukhambha Sanskrit Sansthan, 2011.
20. Sushruta Saṃhitā, Kalpasthāna. Varanasi: Chaukhambha Visvabharati, 2005.
21. Govind Das. Bhaishajya Ratnāvali – Viṣa Chikitsā. Chaukhambha Prakashan, 2015.
22. Subapriya R, Nagini S. Curr Med Chem Anticancer Agents, 2005; 5(2): 149–6.
23. Gupta SC, Patchva S, Aggarwal BB. AAPS J., 2013; 15(1): 195–218.
24. Kokate CK, Purohit AP, Gokhale SB. Pharmacognosy. Pune: Nirali Prakashan, 2019.
25. Bawaskar HS. Scorpion sting: A major health problem in rural Maharashtra. Indian J Med Sci, 2005; 59(3): 120–5.